Zomedica (ZOM) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
4.97 million shs
Average Volume
4.07 million shs
Market Capitalization
$128.67 million
P/E Ratio
Dividend Yield
Price Target
ZOM stock logo

About Zomedica Stock (NYSEAMERICAN:ZOM)

Zomedica Corp is a veterinary health company based in Ann Arbor, Michigan. The company's mission is to improve the health and well-being of pets through innovative diagnostic solutions. Zomedica primarily focuses on developing diagnostic and treatment options for companion animals such as dogs and cats.

Zomedica has been making significant strides in the veterinary industry since its inception in 2015. In 2020, the company announced the launch of its first product, TRUFORMA™, a diagnostic platform that uses bulk acoustic wave sensor technology to provide precise and rapid test results. TRUFORMA™ has already received regulatory approval from the United States Food and Drug Administration (FDA) and is expected to revolutionize the veterinary diagnostic market.

Zomedica Corp has a talented management team with extensive experience in the veterinary and healthcare industries. Larry Heaton is the chief executive officer (CEO) and has over 35 years of operations experience in biotechnology. 

Ann Cotter is the chief financial officer (CFO). Her primary responsibility is planning, implementing and managing Zomedica's finance activities, including business planning, budgeting, forecasting, and negotiations. She served as the company's vice president of finance from August 2018 until October 2020, when she was promoted to her current role.

Zomedica Corp has been steadily growing its revenue over the past few years. However, the company has yet to profit, with a net loss of around $20 million annually for several years. Zomedica has also been taking on debt to fund its operations, doubling its total obligation from Q4 2021 to Q4 2022. Zomedica Corp's valuation metrics are in line with its industry peers. 

The veterinary industry is growing rapidly, with many pet owners seeking high-quality care for their companion animals. According to the American Pet Products Association, Americans spent $261 billion on their pets in 2022, with $99 billion on veterinary care.

Zomedica operates in the veterinary diagnostics market, which is expected to grow at a compounded annual growth rate (CAGR) of 6.1% between 2021 and 2028. The company's primary competitors in this market include IDEXX Laboratories, Heska Corporation and Zoetis Inc.

Zomedica Corp has several growth opportunities in the veterinary industry. The company's TRUFORMA™ platform is expected to drive revenue growth, providing a unique and innovative solution for veterinary diagnostics. The platform can disrupt the traditional laboratory testing model, giving accurate results in minutes rather than hours or days.

In addition to TRUFORMA™, Zomedica is also developing other diagnostic solutions for companion animals. The company's pipeline includes tests for various diseases and conditions, including thyroid disease and cancer.

Zomedica is also exploring opportunities to expand its presence in international markets. The company recently signed an agreement with Veterinary Technology Institute (VTI) to distribute its TRUFORMA™ platform in South Africa.

Zomedica Corp faces several risks and challenges in the highly competitive veterinary industry. The company's success depends on its ability to develop and commercialize new diagnostic solutions that meet the needs of veterinarians and pet owners. If the company can create effective and affordable products, it may be able to compete with larger and more established players in the market.

Zomedica's reliance on third-party suppliers and distributors risks the company's operations. Any supply chain or distribution channel disruptions could significantly impact the company's revenue and profitability.

Zomedica's high debt levels may limit the company's ability to invest in research and development or pursue new growth opportunities. Any changes in interest rates or unfavorable market conditions could also affect the company's ability to service its debt obligations.

ZOM Stock Price History

ZOM Stock News Headlines

Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Q4 2023 Zomedica Corp Earnings Call
Zomedica reports Q4 results
Zomedica Pharmaceuticals Corp (ZOM)
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Zomedica Pharmaceuticals Corp. (ZOM)
Zomedica Corp Ordinary Shares
See More Headlines
Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$25.19 million
Book Value
$0.24 per share


Free Float
Market Cap
$128.67 million
Not Optionable
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Larry C. Heaton II (Age 67)
    President, CEO & Director
    Comp: $617.59k
  • Mr. Peter L. Donato BSBA (Age 54)
    M.B.A., Chief Financial Officer
  • Mr. Anthony K. Blair (Age 63)
    Chief Operating Officer
  • Mr. Evan St. Peter M.B.A.
    Vice President of Technology Innovation
  • Ms. Karen L. DeHaan-Fullerton J.D. (Age 55)
    Chief Counsel & Corporate Secretary
  • Ms. Nicole Westfall M.B.A.
    Senior Vice President of Marketing
  • Mr. Russell Kevin Klass
    Senior Vice President of Sales
  • Ms. Kristin Domanski
    Vice President of Human Resources
  • Mr. Greg Blair
    Senior Vice President of Business Development & Strategic Planning
  • Mr. Robert W. DiMarzo (Age 67)
    Comp: $291.2k

ZOM Stock Analysis - Frequently Asked Questions

How have ZOM shares performed in 2024?

Zomedica's stock was trading at $0.1788 at the beginning of 2024. Since then, ZOM stock has decreased by 26.6% and is now trading at $0.1313.
View the best growth stocks for 2024 here

When is Zomedica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ZOM earnings forecast

How were Zomedica's earnings last quarter?

Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Monday, April, 1st. The company reported ($0.01) EPS for the quarter. The company had revenue of $7.34 million for the quarter, compared to the consensus estimate of $7 million. Zomedica had a negative trailing twelve-month return on equity of 8.13% and a negative net margin of 137.10%.

What guidance has Zomedica issued on next quarter's earnings?

Zomedica updated its FY 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $31.0 million-$35.0 million, compared to the consensus revenue estimate of $34.1 million.

How do I buy shares of Zomedica?

Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ZOM) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners